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Abstract
Background/aim Raloxifene is the first selective estrogen
receptor modulator that has been approved for the treat-
ment and prevention of osteoporosis in postmenopausal
women in Europe and in the US. Although raloxifene
reduces the risk of invasive breast cancer in postmeno-
pausal women with osteoporosis and in postmenopausal
women at high risk for invasive breast cancer, it is
approved in that indication in the US but not in the EU. The
aim was to characterize the clinical profiles of postmeno-
pausal women expected to benefit most from therapy with
raloxifene based on published scientific evidence to date.
Methods Key individual patient characteristics relevant
to the prescription of raloxifene in daily practice were
defined by a board of Swiss experts in the fields of men-
opause and metabolic bone diseases and linked to pub-
lished scientific evidence. Consensus was reached about
translating these insights into daily practice.
Results Through estrogen agonistic effects on bone,
raloxifene reduces biochemical markers of bone turnover
to premenopausal levels, increases bone mineral density
(BMD) at the lumbar spine, proximal femur, and total
body, and reduces vertebral fracture risk in women with
osteopenia or osteoporosis with and without prevalent
vertebral fracture. Through estrogen antagonistic effects on
breast tissue, raloxifene reduces the risk of invasive
estrogen-receptor positive breast cancer in postmenopausal
women with osteoporosis and in postmenopausal women at
high risk for invasive breast cancer. Finally, raloxifene
increases the incidence of hot flushes, the risk of venous
thromboembolic events, and the risk of fatal stroke in
postmenopausal women at increased risk for coronary heart
disease. Postmenopausal women in whom the use of
raloxifene is considered can be categorized in a 2 9 2
matrix reflecting their bone status (osteopenic or osteopo-
rotic based on their BMD T-score by dual energy X-ray
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absorptiometry) and their breast cancer risk (low or high
based on the modified Gail model). Women at high risk of
breast cancer should be considered for treatment with
raloxifene.
Conclusion Postmenopausal women between 50 and
70 years of age without climacteric symptoms with either
osteopenia or osteoporosis should be evaluated with regard
to their breast cancer risk and considered for treatment with
raloxifene within the framework of its contraindications
and precautions.
Keywords Raloxifene  Breast cancer  Osteoporosis 
Fractures
Introduction
Raloxifene, the first selective estrogen receptor modulator
(SERM), induces agonistic and antagonistic estrogenic
effects in tissues expressing the estrogen receptor (ER).
Raloxifene is approved for the treatment and prevention of
osteoporosis in postmenopausal women in the US, EU, and
Switzerland. In the latter, the indication section stipulates
that treatment initiation with raloxifene for the prevention
of postmenopausal osteoporosis requires a T-score of -1
SD or less measured by dual energy X-ray absorptiometry
(DXA) at either the lumbar spine or the distal forearm [1].
In 2007, raloxifene was approved for the reduction in risk
of invasive breast cancer in postmenopausal women with
osteoporosis and in postmenopausal women at high risk for
invasive breast cancer in the US [2]. To the best of our
knowledge, such an indication has not been sought by the
manufacturer neither in the EU nor in Switzerland to date.
Since marketing authorization was granted by North
American and European registration agencies, four major
international clinical endpoint trials with raloxifene have
been completed and published: the Multiple Outcomes of
Raloxifene Evaluation (MORE) trial [3], the Continuing
Outcomes Relevant to Evista (CORE) trial [4], the
Raloxifene Use for the Heart (RUTH) [5], and the Study of
Tamoxifen and Raloxifene (STAR) [6] trials. These trials
included more than 37,000 postmenopausal women with
various clinical risk profiles, including long-term follow-up
data up to 8 years [7, 8] so that raloxifene belongs to the
best studied pharmacotherapies in this patient population.
Fully acknowledging the wealth of efficacy and safety
data available for raloxifene but also recognizing that not
every woman with a T-score below -1 SD will or can be
prescribed this therapy, a clinically important challenge in
the daily practice of physicians in charge of postmeno-
pausal women care is to identify those women expected to
benefit most from such an intervention. In order to asser-
tively recommend or not the daily intake of raloxifene, the
decision-making process should ideally rely on available
evidence encompassing all facets of the drug’s profile,
including its effects on bone and invasive breast cancer risk
as well as its safety and tolerability aspects.
The aim of the present review was to characterize the
clinical profiles of postmenopausal women expected to
benefit most from therapy with raloxifene based on pub-
lished scientific evidence to date. An advisory board
composed of Swiss experts in the fields of menopause and
metabolic bone diseases was held in March 2011. In a first
step, key individual patient characteristics relevant to the
prescription of raloxifene in daily practice were identified
(Table 1) and linked to published scientific evidence
summarized below. Thereafter, a consensus was reached
about how these insights could be translated into clinical
decision-making in daily practice.
Clinical trials with raloxifene: effects on fracture risk
The World Health Organization (WHO) defined osteopo-
rosis as ‘‘a systemic skeletal disease characterized by low
bone mass and micro-architectural deterioration of bone
tissue, with a consequent increase in bone fragility and
susceptibility to fracture’’ [9]. The most frequent compli-
cations of the disease are the ‘‘typical’’ osteoporotic frac-
tures occurring at the hip, spine, distal forearm, and
proximal humerus. Furthermore, the WHO proposed an
operational definition of osteoporosis as a bone mineral
density (BMD) that lies 2.5 standard deviations or more
below the average mean value of young healthy women
(T-score B-2.5 SD) [9, 10]. Osteopenia was defined as a
BMD T-score at or below -1.0 SD and higher than -2.5
SD [9, 10].
Table 1 Key patient characteristics underlying the decision of rec-
ommending/prescribing raloxifene or not in postmenopausal women
in daily practice
Age
Presence or absence of climacteric symptoms
Fracture risk
T-score measured by DXA
FRAX-score
Breast cancer risk
Cardiovascular risk
Risk of venous thromboembolic event (VTE)
Risk of acute coronary event (AGLA scorea)
Risk of stroke (Framingham Stroke Risk Score)
a The AGLA score (10-year risk for an acute coronary event) was
derived from the PROCAM-score corrected for epidemiological
specificities in the Swiss setting
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Treatment of postmenopausal osteoporosis
The effects of raloxifene on fracture incidence and BMD in
postmenopausal women with osteoporosis were examined
at 3 years in a large randomized, placebo-controlled,
double-blind, multinational osteoporosis treatment trial
(the MORE trial [3]). The study population consisted of
7,705 postmenopausal women with osteoporosis as defined
by either a BMD T-score B-2.5 SD at the lumbar spine or
the hip without vertebral fractures at baseline or by the
presence of one or more vertebral fractures baseline.
Women enrolled in this study had a median age of 67 years
(range 31–80) and a median time since menopause of
19 years. Compared to placebo, treatment with raloxifene
significantly increased BMD at the lumbar spine and the
hip at all time points of measurement (12, 24, and
36 months). After 36 months, the risk of morphometric and
clinical new vertebral fractures was significantly reduced
by 30–50 % with raloxifene compared to placebo. In the
fourth year, fracture risk reduction was similar to that in the
first 3 years [11]. Furthermore, a post hoc analysis of the
subgroup of patients included in MORE, who had osteo-
penia or osteoporosis diagnosed based on their BMD T-
score at the hip and no prevalent vertebral fractures at
baseline, and were treated with raloxifene 60 mg/day
during 3 years, showed a significant reduction in clinical
vertebral fracture risk in osteopenic as well as osteoporotic
women [12]. Non-vertebral fractures including hip, wrist,
and ankle fractures, were numerically less frequent in the
raloxifene group but the difference to the placebo group did
not reach statistical significance [3]. In a post hoc analysis
of the MORE study at 3 years which evaluated the asso-
ciation between vertebral fracture severity at baseline and
the risk of new vertebral and non-vertebral fractures, ra-
loxifene 60 mg/day was shown to significantly reduce the
risks of new vertebral as well as new non-vertebral frac-
tures in patients with severe pre-existent vertebral fractures
by 26 % (p = 0.048) and 47 % (p = 0.046), respectively
[13]. These findings were recently corroborated by reana-
lyzing the anti-fracture efficacy of raloxifene as a function
of individual fracture risk assessed by FRAX (plus BMD)
at baseline (see below) [14]. This analysis showed that the
effectiveness of raloxifene for clinical fractures was com-
parable over the whole range of FRAX probabilities [14].
While this finding is consistent with earlier observations
showing the absence of interaction between baseline BMD
and the magnitude of treatment efficacy with raloxifene
[12] and no difference in efficacy between women with or
without clinical risk factors for osteoporosis [15], they are
not consistent with results obtained with the bisphospho-
nate clodronate [16] and with another SERM, bazedoxifene
[17], where treatment efficacy was greater at higher frac-
ture probabilities. The reasons for these discrepant findings
are speculative and have been discussed earlier [12, 14].
Based on currently available evidence and consistent
with the detailed indication of raloxifene in Switzerland,
‘‘treatment of osteoporosis with raloxifene results in
a reduction of incident vertebral fractures. A reduction
of incident non-vertebral fractures has remained so far
unproven’’ [1].
The CORE trial examined the effect of four additional
years of raloxifene therapy on the incidence of invasive
breast cancer in women in MORE who agreed to continue
[4, 18]. In CORE, women assigned to raloxifene in MORE
(n = 3,510) were assigned to receive raloxifene 60 mg/
day, while women assigned to placebo continued on pla-
cebo (n = 1,703). Concomitant use of bone active agents
was permitted in the fourth year of MORE and during
CORE [7]. Although raloxifene maintained the increases of
lumbar spine and femoral neck BMD over 7 years after
randomization in MORE, no effect on non-vertebral frac-
ture risk was shown after 8 years [7]. However, it should be
noted that the CORE trial had important limitations
regarding skeletal endpoints because of its design as a
breast cancer prevention study, of the predominant use of
bone active substances in the placebo group, and of
included patients being at lower risk of non-vertebral
fractures than those included in fracture endpoint trials
with bisphosphonates, such as the fracture intervention trial
(FIT) with alendronate [7, 19] or the HORIZON trial with
zoledronate [20].
Finally, in the RUTH trial, in which women were
selected based on their increased risk for coronary events,
the risk of clinical vertebral fractures (secondary endpoint)
was significantly reduced by 35 % (hazard ratio 0.65, 95 %
CI 0.47–0.89) with raloxifene 60 mg/day compared to
placebo after a median follow-up of 5.6 years [21].
Prevention of postmenopausal osteoporosis
When leaving hormone replacement therapy out of con-
sideration, SERMs, of which raloxifene, are the only bone
active substances currently indicated and reimbursed in
Switzerland for the prevention of postmenopausal osteo-
porosis in women with a T-score at or below -1.0 SD
measured by DXA.
The effects of raloxifene on BMD in postmenopausal
women were examined in two randomized, placebo-con-
trolled, double blind osteoporosis prevention trials of
2 years duration: a European [22] and a North American
trial [23] of similar design which enrolled 601 and 544
women, respectively. In these trials, all women received
calcium supplementation (400–600 mg/day). Women
enrolled had a mean age of 55 years (range 45–60 years)
and a mean time since menopause of 5 years (from less
than 1 up to 15 years). Mean BMD T-score at inclusion
Eur Spine J (2012) 21:2407–2417 2409
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ranged from -1.01 to -0.74 at the lumbar spine so that
women both with normal BMD and osteopenia were
included. Raloxifene 60 mg/day produced statistically
significant increases in hip, spine, and total body BMD
versus calcium supplementation alone already 12 months
after initiation of therapy, an effect which was maintained
at 24 [22], 36 [23], and 60 [24] months after initiation of
therapy. Consistent findings were reported in another ran-
domized placebo- and active-controlled trial in 619 hys-
terectomized postmenopausal women [25].
Raloxifene and FRAX
Recently, the use of fracture probability assessment algo-
rithms based on clinical risk factors has been shown to
enhance the performance of BMD in the prediction of hip and
osteoporotic fractures in men and women [26]. In order to
identify the major clinical risk factors for osteoporotic frac-
ture, the data from 9 prospective primary cohorts and 11
prospective validation cohorts, including more than 275,000
persons corresponding to 1.4 million person-years with more
than 22,711 reported fractures were analyzed [26]. The val-
idation analysis included the results from the Swiss SEMOF-
cohort [27]. In addition to any prior fragility fracture that
occurred after age 50, age, sex, and body mass index, further
risk factors were considered. These included prior use of
glucocorticoids, secondary osteoporosis, rheumatoid arthritis,
a history of parental hip fracture, current cigarette smoking,
and alcohol intake of 3 or more units/day. These factors were
identified as clinical predictors of osteoporotic fracture
probability [26]. Taking into account local epidemiological
data, the impact of these risk factors on the 10-year absolute
probability of fracture allows for country-specific prediction
of individual fracture probability, based on the individual risk
factor profile. This case-finding algorithm developed in col-
laboration with the WHO, known as FRAX (http://
www.shef.ac.uk/FRAX), has been calibrated for Swiss-
specific fracture probability and life expectancy [28–30].
Recently, the skeletal effects of raloxifene versus pla-
cebo on the risk of all clinical fractures and morphometric
vertebral fractures in MORE were evaluated as a function
of baseline fracture risk assessed by FRAX [14]. The
10-year probability of major osteoporotic fractures (with
BMD) at baseline ranged from 0.9 to 77.2 %. Compared to
placebo, treatment with raloxifene was associated with an
18 % decrease in all clinical fractures treatment
(p = 0.0063) and a 42 % decrease in new morphometric
vertebral fractures (p \ 0.001) over the whole range of
fracture risk at baseline. Furthermore, another singularity
was that although vertebral fracture risk was reduced at all
ages the efficacy of raloxifene on vertebral fracture risk
was significantly greater in women younger than 75 years
of age [14]. However, as absolute risk reduction increased
with age and with the FRAX score in all age groups, high
risk women should also be targeted for treatment.
In summary, raloxifene acts as an estrogen agonist in
bone. Raloxifene reduces biochemical markers of bone
turnover to premenopausal levels [3, 11, 22, 23], increases
BMD at the lumbar spine, proximal femur, and total body
[3, 22–24, 31] and reduces vertebral fracture risk in women
with osteopenia (BMD T-score at or below -1.0 SD and
higher than -2.5 SD) or osteoporosis (BMD T-score
B-2.5 SD) with and without prevalent vertebral fracture
[3, 12, 21, 31]. FRAX plus BMD might contribute to
targeting intervention at younger women with clinical risk
factors and to identifying women at highest risk [14].
Clinical trials with raloxifene: effects on the incidence
of invasive breast cancer
At a very early stage of drug development, during MORE,
it became evident that raloxifene may play an important
role in reducing the incidence of invasive breast cancer in
postmenopausal women. In the MORE trial, 13 cases of
breast cancer were confirmed among the 5,129 women
assigned to raloxifene versus 27 among the 2,576 women
assigned to placebo, corresponding to a 76 % relative risk
reduction (p \ 0.001) [32]. Raloxifene decreased the risk
of estrogen-receptor (ER) positive breast cancer by 90 %
and had no effect on ER-negative breast cancer incidence
[32]. Its effect was greater in women with detectable
baseline serum estradiol levels [10 pg/ml [33].
Later, these findings were confirmed in the CORE trial,
a follow-up to the MORE trial, with invasive breast cancer
now the primary endpoint. During the 4 years of the CORE
trial, 31 cases of breast cancer were confirmed in the 3,510
women on raloxifene versus 30 in the 1,703 women on
placebo [4]. Over the 4 years of the CORE trial, the overall
incidence of breast cancer, regardless of invasiveness, was
reduced by 50 % (p = 0.005) in the raloxifene group
compared with the placebo group [4]. The incidence of
invasive breast cancer was significantly reduced by 59 %
(p \ 0.001) and the incidence of invasive estrogen-recep-
tor positive breast cancer by 66 % (p \ 0.001) [4].
Raloxifene had no effect on the incidence of non-invasive
breast cancer and of ER-negative breast cancer. Similar
observations were made in the full MORE and CORE
cohort followed over 8 years [4]. Raloxifene therapy was
associated with a reduced breast cancer risk in both women
at lower and those at higher breast cancer risk [18].
Raloxifene was especially effective in women with higher
estrogen levels at baseline, older than 65 years of age, and
a history of breast cancer in their first-degree relatives [18].
In the RUTH trial which recruited postmenopausal
women at increased risk of coronary events, raloxifene
2410 Eur Spine J (2012) 21:2407–2417
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reduced the risk of invasive breast cancer in lower risk,
older women by 44 % (p = 0.003) [5, 34]. Similar to the
findings in the MORE and CORE trials, raloxifene exclu-
sively reduced the incidence of estrogen-receptor positive
invasive breast cancer, representing the majority of all
diagnosed cancers, by 55 % (p \ 0.001) [5, 34].
Finally, the National Surgical Adjuvant Breast and
Bowel Project (NSABP) conducted the prospective,
double-blind, randomized, active-controlled Study of
Tamoxifen and Raloxifene (STAR) [6, 35] which included
19,747 postmenopausal women (82 % of them between 50
and 69 years of age) at high risk for developing breast
cancer. Based on the modified Gail model, high risk of
breast cancer was defined as: at least one breast biopsy
showing lobular carcinoma in situ (LCIS) or atypical
hyperplasia; one or more first-degree relatives with breast
cancer; or a 5-year predicted risk of breast cancer C1.66 %.
Participants were randomly assigned to receive either
tamoxifen at a dose of 20 mg/day or raloxifene 60 mg/day
over 5 years. The primary endpoint was the incidence of
invasive breast cancer. After a median of 3.2 years of
therapy in the STAR trial, the incidence of invasive breast
cancer was 4.3 per 1,000 versus 4.4 per 1,000 (RR = 1.02;
95 %CI, 0.82 to1.28) in the groups assigned to tamoxifen
and raloxifene, respectively [6]. There were fewer cases of
non-invasive breast cancer in the tamoxifen group (57
cases) than in the raloxifene group (80 cases), even if this
difference did not reach statistical significance [6]. Keeping
in mind that non-invasive breast cancer is not a life-
threatening event, these findings are consistent with earlier
results showing that tamoxifen reduces the risk of non-
invasive breast cancer in women aged 35 years and older at
high risk for breast cancer [36]. On the other hand, as
shown in STAR, raloxifene had similar effectiveness as
tamoxifen in reducing the risk of progression to invasive
breast cancer for women who entered the trial with a his-
tory of either lobular carcinoma in situ or atypical hyper-
plasia [6].
In summary, raloxifene acts as an estrogen antagonist in
breast tissue. Raloxifene reduces the risk of invasive
estrogen-receptor positive breast cancer in postmenopausal
women with osteoporosis [4, 32] and in postmenopausal
women at high risk for invasive breast cancer [6]. Evidence
regarding the effects of raloxifene in the treatment of
invasive breast cancer and the reduction of risk of recur-
rence of breast cancer is insufficiently substantiated.
Other gynecologic effects of raloxifene
The incidence of uterine bleeding, endometrial hyperplasia,
and uterine cancer was comparable to that under placebo
in the MORE–CORE and RUTH trials [4, 5, 8]. In the
STAR trial, the incidence of endometrial hyperplasia was
significantly lower with raloxifene compared to tamoxifen
(RR = 0.16, 95 %CI 0.09–0.29) [6]. Uterine cancers were
numerically less with raloxifene but this difference did not
reach statistical significance (annual incidence of 1.25 vs.
2.00 per 1,000 women, RR 0.62, 95 %CI 0.35–1.08) [6].
The latter non-significant trend may be explained by the
significantly lower number of women undergoing hyster-
ectomy under raloxifene vs. tamoxifen (111 vs. 244, RR
0.44, 95 %CI 0.35–0.56) [6].
In addition, the incidence of ovarian cancer was com-
parable to that under placebo in the MORE–CORE and
RUTH trials [5, 8].
Overall, it can safely be stated that raloxifene has no
detrimental effects on the endometrium.
Clinical trials with raloxifene: safety profile
Venous thromboembolic events
Venous thromboembolic events (VTE), including deep
vein thrombosis, retinal vein thrombosis, and pulmonary
embolism are serious albeit uncommon adverse events
reported with raloxifene in all major endpoint trials. Of the
4,011 participants in MORE–CORE, after 8 years of
therapy with either raloxifene (n = 2,725) or placebo
(n = 1,286), VTEs were 1.7-fold more frequent with
raloxifene [absolute VTE rates of 2.2 and 1.3 per 1,000
women-years (p = 0.094), respectively] [4]. Deep vein
thrombosis and retinal vein thrombosis were numerically
more frequent with raloxifene without reaching statistical
significance (31 vs. 10 and 6 vs. 2 cases, respectively).
However, pulmonary embolism was significantly more
frequent with raloxifene (17 vs. 2 events, p = 0.048) [4].
Comparable increases in VTE risk were reported in the
RUTH trial [5]. It was suggested that VTE risk might be
greatest within the first months of initiation of therapy.
However, this observation from the MORE study has nei-
ther been confirmed in subsequent analyses nor in major
clinical trials [8, 37]. In STAR, the incidence of VTE was
significantly lower with raloxifene than with tamoxifen
[RR = 0.70 (95 %CI 0.54–0.91); 2.61 vs. 3.71 events per
1,000 women-years, respectively] [6]. Advanced age,
immobilization, surgery, trauma, and cancer belong to the
most important risk factors for VTE. Two-thirds of the
women who presented a VTE in the MORE trial had one of
these risk factors, most commonly immobilization [38].
Therefore, raloxifene should not be used in women with a
history or at increased risk of VTE. It should be stopped
before and during periods of immobilization such as for
surgery or trauma [37].
In summary, raloxifene increases the risk of VTE and is
contra-indicated in patients with present or past deep vein
Eur Spine J (2012) 21:2407–2417 2411
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thrombosis, retinal vein thrombosis, pulmonary embolism,
or presenting typical risk factors for VTE.
Acute coronary events
Raloxifene lowers total and low density lipoprotein cho-
lesterol and the ratio of apolipoprotein B to apolipoprotein
A1 [22, 25, 39], all known as established risk factors for
coronary heart disease. In MORE and MORE–CORE, ra-
loxifene had no effect on the incidence of coronary events
reported as safety but not primary endpoints [5, 40].
Postmenopausal women included in the RUTH trial were at
increased risk for coronary events defined as either the
presence of established coronary heart disease or a car-
diovascular risk score of 4 points or more according to a
point system taking into account the following: established
CHD (4 points), arterial disease of the leg (4 points), an age
of at least 70 years (2 points), diabetes mellitus (3 points),
cigarette smoking (1 point), hypertension (1 point), and
hyperlipidemia (1 point) [5]. Compared to placebo, ra-
loxifene did not reduce the risk of coronary events (death
from coronary causes, myocardial infarction or hospital-
ization with an acute coronary syndrome), the primary
endpoint (hazard ratio 0.95, 95 %CI 0.84–1.07). However,
in contrast to clinical endpoint trials conducted with
estrogen–progestin regimens [41, 42], raloxifene did not
increase coronary risk in these patients.
In summary, raloxifene does not significantly affect the
risk of coronary heart disease.
Stroke
A surprising finding of the RUTH trial was that raloxifene
was associated with an increased risk of fatal stroke versus
placebo (59 vs. 39 events during 5.6 years of observation,
hazard ratio 1.49, 95 %CI 1.00–2.24, p = 0.05) [5]. Such
an increased incidence of fatal stroke was neither found in
the MORE trial [43] nor in any other major trial [5, 8]. As
in the MORE and MORE–CORE trials, the overall inci-
dence of stroke was not significantly different between
groups [5, 8, 43]. It was suggested that this inconsistent
finding could be related to the heterogeneity in risk in the
patient populations included in MORE–CORE and RUTH.
That is, the higher prevalence of hypertension and diabetes
in women included in RUTH compared to women included
in MORE–CORE (31 vs. 78 % and 3 vs. 46 %, respec-
tively) [5, 37, 40]. Furthermore, a post hoc analysis of the
RUTH results showed that women with a Framingham
Stroke Risk Score (FSRS) \13 showed no increase in ra-
loxifene-associated fatal stroke risk, suggesting that even in
women at high risk for coronary events, those at highest
risk for stroke may be exposed to a risk of fatal stroke [44].
The FSRS estimates the risk for first stroke based on age,
systolic blood pressure, presence of diabetes and non-
cerebrovascular disease, cigarette smoking, atrial fibrilla-
tion and left ventricular hypertrophy [44].
In daily practice in Switzerland, the 10-year risk for an
acute coronary event in postmenopausal women is calcu-
lated using the widely recommended AGLA score devel-
oped by the Working Group on Lipids and Atherosclerosis
of the Swiss Society of Cardiology [45]. The AGLA score
was derived from the German PROCAM score [46, 47] by
adapting the algorithms to the Swiss setting. Based on the
AGLA score, the 10-year probability for a coronary event
can be categorized into low (\10 %), moderate (10–20 %)
and high risk ([20 %) based on the following risk items:
age, systolic blood pressure, presence of diabetes, history
of myocardial infarction before the age of 60 years in a first
grade relative, cigarette smoking, serum levels of LDL and
HDL cholesterol, and serum triglycerides [45].
Therefore, while some input parameters of the FSRS and
the AGLA score overlap, others do not. Special attention
should be given to the latter, i.e., the presence of a personal
history of cardiovascular disease, atrial fibrillation, and left
ventricular hypertrophy.
Taken together, raloxifene increased the risk of fatal
stroke in postmenopausal women at increased coronary risk
[5] but not in postmenopausal women with osteoporosis
who were at low risk for coronary events [5, 8, 43]. In
postmenopausal women at increased coronary risk,
raloxifene should be used after cautious consideration of
the risk–benefit balance in women at increased risk of
stroke, including those with a personal history of cerebro-
vascular disease (stroke and transient ischemic attacks),
atrial fibrillation, hypertension, and in those who smoke.
Overall mortality
A pooled analysis of mortality data was performed from
large clinical trials of raloxifene (60 mg/day) versus pla-
cebo [48]. In the MORE–CORE trials, there were 45 deaths
among women assigned to raloxifene 60 mg/day versus 65
among women assigned to placebo. Overall mortality was
32 % lower among participants assigned to raloxifene
60 mg/day versus placebo (1.8 vs. 2.5 %; p = 0.04) with a
lower rate of deaths due to cancer (0.5 vs. 1.0 %; p = 0.04)
and a non-significant difference in deaths due to cardio-
vascular causes (0.6 vs. 0.8 %). In the RUTH trial, overall
and cardiovascular mortality did not differ between treat-
ment groups. However, cerebrovascular mortality was
significantly greater (1.2 vs. 0.8 %; p = 0.05) and non-
cardiovascular mortality significantly lower (3.7 vs. 4.6 %;
p = 0.03) in the raloxifene group [48].
2412 Eur Spine J (2012) 21:2407–2417
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Other patient characteristics for raloxifene treatment
eligibility
Climacteric symptoms
Hot flushes were significantly more frequent in women
receiving raloxifene 60 or 120 mg/day (9.7 and 11.6 %,
respectively) than in women receiving placebo (6.4 %,
p \ 0.001) in the MORE trial. These findings were con-
firmed in the CORE trial (12.6 vs. 6.9 %, p \ 0.001) and in
the RUTH trial (8.0 vs. 4.8 %, p \ 0.001). In osteoporosis
prevention studies, i.e., in younger women with shorter
time since menopause than those included in the four major
endpoint trials, hot flushes were numerically but not sig-
nificantly more frequent in women on raloxifene than on
placebo (24.6 vs. 18.3 % [49] and 26.3 vs. 22.7 % [22],
respectively). These findings are consistent with the results
of a randomized controlled trial aimed at evaluating the
potential of raloxifene to induce or exacerbate hot flushes:
487 postmenopausal women were randomized to either
treatment for 8 months with raloxifene or placebo. At
baseline, 40.4 % of all randomly assigned patients had hot
flushes. Shorter time since menopause, surgical meno-
pause, and previous estrogen-based therapy were signifi-
cant predictors of hot flushes at baseline but not of incident
hot flushes during treatment with raloxifene [50]. Slow-
dose escalation (i.e. 60 mg of raloxifene every other day
during 2 months before increasing to standard dose of
60 mg/day) was suggested to reduce the incidence of hot
flushes [51]. Therefore, the ideal raloxifene patient should
be a postmenopausal woman which presents without cli-
macteric symptoms at the time of treatment initiation.
Age
Although experience with raloxifene in clinical trials
covers an age range between 31 and 92 years, the vast
majority of patients included in major clinical endpoint
trials were postmenopausal women aged between 50
and 70 years (Table 2). Therefore, the typical raloxifene
patient is a post-menopausal woman between 50 and 70
years of age. Taking into account climacteric symptoms
(see below), the lower boundary of this age range may
rather be 52 to 55 years.
In summary, the typical raloxifene patient is a post-
menopausal woman between 50 and 70 years of age. As
raloxifene increases the incidence of hot flushes, it seems
appropriate to recommend treatment initiation with
raloxifene in daily practice only in women not presenting
with hot flushes.
Recommendations for the use of raloxifene in daily
practice in the Swiss setting
Based on these considerations, the approach below was
developed for identifying postmenopausal women in whom
raloxifene may be prescribed on a routine basis in daily
practice.
Step 1: which women should be evaluated?
All postmenopausal women between 50 and 70 years of
age who do not present with climacteric symptoms.
Table 2 Synopsis of the major randomized controlled endpoint trials designs with raloxifene in postmenopausal women
MORE [3] CORE [4] STAR [5] RUTH [6]
Duration of
observation
40 months 48 months 47 months 5.6 years
n randomized
(n by treatment groups)
7,705 (5,129 raloxifene
2,576 placebo)
4,011 (2,725
raloxifene,
1,286 placebo)
19,747 (9,745
raloxifene, 9,726
tamoxifen)
10,101 (5,044 raloxifene, 5,057
placebo)
Age at inclusion
(years)
Mean 66.5
SD 7.0
Range 31–80
Mean 65.8
SD 6.8
Mean 58.5
SD na
Range 35–83 (72 % were
between 50 and 70)
Mean 67.5
SD 6.6
Range 55–92 (39 % were C70)
Main inclusion
criteria
Documented osteoporosis
(T -score B-2.5 SD at
LS or FN or low BMD
and vertebral fracture)
Subset of MORE 5-year predicted breast cancer
risk C1.66 based on the Gail
model
Established coronary heart disease
or at increased risk for major
coronary events
Primary endpoint Vertebral fractures
LS and FN BMD
Invasive breast
cancer
Invasive breast cancer Coronary events, Invasive breast
cancer
MORE Multiple Outcomes of Raloxifene Evaluation, CORE Continuing Outcomes Relevant to Evista, STAR Study Of Tamoxifen and
Raloxifene, RUTH Raloxifene Use for the Heart
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Step 2: when should raloxifene not be used?
Raloxifene is contraindicated in patients with current or
past history of venous thromboembolism, including
deep vein thrombosis, retinal vein thrombosis, pulmonary
embolism, or presenting typical risk factors for venous
thromboembolic events.
Raloxifene should be used cautiously in women at high
risk for coronary events (AGLA score [20 %). In these
patients, the increased risk of fatal stroke may be limited to
those with Framingham Stroke risk Score C13.
In addition, raloxifene should be avoided in women
presenting with vasomotor symptoms.
According to the Swiss prescribing information of EVI-
STA, raloxifene is contra-indicated in pregnant women; in
women with current or past history of venous thromboem-
bolism, including deep vein thrombosis, retinal vein
thrombosis, and pulmonary embolism; in women with
hypersensitivity against raloxifene or any of the components
of the tablet; in women with liver insufficiency, including
cholestasis, or severe renal insufficiency; in women with
uterine bleedings of unknown origin; and in women with
clinical signs or symptoms of endometrial carcinoma.
Step 3: how should these women be evaluated?
Based on its currently reimbursed indication in Switzer-
land, raloxifene [EVISTA (raloxifene hydrochloride)]
will preferably be used for the treatment and prevention of
osteoporosis with a BMD T -score of -1.0 SD or less or in
the presence of fracture [52]. Thus, decision-making should
first rely on the categorization of patients as either oste-
openic or osteoporotic, based on the operational definitions
proposed by the WHO [53]. Thereafter, individual breast
cancer risk should be evaluated based on the modified Gail
model [54, 55] used for inclusion in the STAR trial [6].
High risk for breast cancer was defined as at least one
breast biopsy showing LCIS or atypical hyperplasia, one or
more first-degree relatives with breast cancer, or a 5-year
predicted risk of breast cancer C1.66 % [2].
As shown in Fig. 1, postmenopausal women in whom
the use of raloxifene is considered can be categorized in a
2 9 2 matrix reflecting their bone status (osteopenic or
osteoporotic based on their BMD T-score by DXA) and
their breast cancer risk (low or high based on the modified
Gail model).
In women with osteopenia and at low risk for breast
cancer, the decision of using raloxifene (or not) will pri-
marily rely on clinical judgment. This decision may be
supported by increased levels of biochemical markers of
bone turnover. Casually, a high FRAX score may give
some orientation, while keeping in mind that the FRAX
algorithm calculates the clinical risk factor based individ-
ual 10-year probability of either hip or major osteoporotic
fracture (pooled hip, clinical spine, distal radius, and
proximal humerus fractures). Thus, FRAX does not pro-
vide an estimate of the individual 10-year probability of
suffering a (morphometric or clinical) vertebral fracture,
while raloxifene was consistently shown to reduce mor-
phometric vertebral fracture risk only.
In women with a T-score at or below -2.5 SD with or
without prevalent vertebral fractures bisphosphonates [19,
20, 56] and more recently the monoclonal antibody deno-
sumab [57] have been shown to consistently reduce the risk
of vertebral and non-vertebral fractures, including hip frac-
tures. Even in the absence of direct comparative fracture
endpoint trials between raloxifene and these substances, it
seems reasonable to assume that bisphosphonates and
Postmenopausal women
50 –70 years old
No climacteric symptoms
Consider raloxifene if high 
bone turnover and/or
high FRAX®-score
Low
Breast cancer risk*
High
Consider raloxifene in 
younger women with no 
prevalent fractures and a 
non-osteoporotic T-score at 
the hip
Prescribe raloxifene and 
evaluate a combination
with a bone active
substance
(refer to bone specialist)
Prescribe raloxifene
Osteopenia
(≤ -1.0 SD and 
>-2.5 SD)
BM
D
 T
-s
co
re
 b
y 
DX
A
Osteoporosis
(≤ -2.5 SD)
Evaluate contra-indications and precautions**:
Current or past history of venous thrombomboembolism
Increased risk for stroke
Algorithm for prescribing raloxifene in daily routineFig. 1 Algorithm for raloxifene
use in daily practice. *High risk
of breast cancer defined as at
least one breast biopsy showing
lobular carcinoma in situ (LCIS)
or atypical hyperplasia, one or
more first-degree relatives with
breast cancer, or a 5-year
predicted risk of breast cancer
C1.66 % (based on the modified
Gail model).**Refer to text and
full prescribing information for
detailed contra-indications
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denosumab may have a superior efficacy profile in this
patient population in which the primary goal of therapy is to
reduce vertebral as well as non-vertebral fracture risk.
Therefore, in women with osteoporosis and at low risk for
breast cancer, raloxifene can be considered for younger
women without prevalent vertebral fractures and a non-
osteoporotic T-score at the hip.
In women with osteopenia and at high risk of breast
cancer, raloxifene can be broadly recommended in daily
practice for the vast majority of eligible women without
contra-indications. In this patient population, raloxifene
preserves BMD [22, 23, 25] and reduces the risk of new
vertebral fractures, including clinical fractures [3, 11] as well
as the risk of incident invasive breast cancer [4–6, 32].
Interestingly, the cost-effectiveness of raloxifene was eval-
uated in the UK healthcare setting considering for the first
time its effects on bone and on the breast [58]. Raloxifene
was shown to be cost-effective in cohorts of young post-
menopausal women, who do not meet the 10-year fracture
risk threshold suggested by the British National Osteoporo-
sis Foundation because cost-effectiveness was contingent on
their 5-year invasive breast cancer risk. The result highlights
the importance of considering a woman’s full risk profile
when considering anti-osteoporosis treatment [58].
Similar considerations apply to postmenopausal women
with osteoporosis and a high risk of breast cancer. How-
ever, the combination of raloxifene with a bone active
substance proven to reduce also non-vertebral and hip
fracture risk should be considered. The combination ther-
apy with raloxifene and alendronate was evaluated in a
randomized active-controlled 12-month trial in 331 post-
menopausal women with a BMD T-score below -2.0 SD at
the femoral neck [59]. The association of raloxifene ?
alendronate reduced bone turnover more than either drug
alone, resulting in greater BMD increment. Whether these
additive effects would result in improved anti-fracture
efficacy could not be shown by this trial. However, bene-
ficial effects on bone volume resulting in improved struc-
tural properties of vertebral bone were demonstrated with
the combination of alendronate ? raloxifene in rats [60].
Thus, the available evidence regarding the efficacy of
raloxifene combined with another bone active substance is
scarce and its safety with regard to the potential risk of
over-suppression of bone turnover is unknown. In daily
practice, the decision to use a combination of raloxifene
and a bone active substance should rely on prior advice of a
bone specialist.
Conclusions
Postmenopausal women between 50 and 70 years of age
without climacteric symptoms with either osteopenia or
osteoporosis should be evaluated with regard to their breast
cancer risk. Women at high risk of breast cancer should
be considered for treatment with raloxifene within the
framework of its contraindications (VTE) and precautions
(stroke risk).
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